For example, 21 ARGs that target the autophagy maturation stage are of interest in developing novel combinational therapies in that effectively blocking autophagy maturation inhibits autophagy-promoted survival of CML cells, thereby enhancing the sensitivity of CML cells to BCR-ABL inhibitors such as IM29,75. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.